Datasheet

EVER2 Antibody
CATALOG NUMBER: 4605

Availability: In stock

$0.00
Product Price Options
$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
TESTED APPLICATIONS:ELISA, IF, IHC-P, WB
APPLICATIONS:EVER2 antibody can be used for detection of EVER2 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1205 - Jurkat Cell Lysate
 2) Cat. No. 10-301 - Human Brain Tissue Slide
SPECIFICITY:At least three isoforms of EVER2 are known to exist; this antibody will only recognize the larger isoform. EVER2 has no cross-reactivity to EVER1.
IMMUNOGEN:EVER2 antibody was raised against a 14 amino acid synthetic peptide from near the center of human EVER2.

The immunogen is located within amino acids 300 - 350 of EVER2.
HOST SPECIES:Rabbit

Properties

PURIFICATION:EVER2 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:EVER2 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:EVER2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:EVER2 Antibody: EV2, EVER2, EVIN2, Transmembrane channel-like protein 8, Epidermodysplasia verruciformis protein 2
ACCESSION NO.:AAM44454
PROTEIN GI NO.:25527192
OFFICIAL SYMBOL:TMC8
GENE ID:147138

Background

BACKGROUND:EVER2 Antibody: Epidermodysplasia verruciformis (EV) is an autosomal recessive genodermatosis associated with a high risk of skin cancers resulting from a high susceptibility to infection by specific human papillomaviruses. Mutations in two homologous genes EVER1 and EVER2 cause the majority of EV cases. These two proteins form a complex and interact with the zinc transporter ZnT-1 in the endoplasmic reticulum. Cells lacking EVER2 accumulated higher levels of zinc in the nucleolus and nucleus compare to those cells with and intact EVER2 gene, indicating that one role of EVER2 is to regulate the intracellular distribution of zinc.
REFERENCES: 1) Ramoz N, Taieb A, Rueda L-A, et al. Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. J. Invest. Dermatol.2000; 114:1148-53.
2) Ramoz N, Rueda L-A, Bouadjar B, et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat. Genet.2002; 32:579-81.
3) Lazarczyk M, Pons C, Mendoza J-A, et al. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J. Exp. Med.2008; 205:35-42.

For Research Use Only